October 14, 2013

Guideline Title

Evidence-based guideline: treatment of parenchymal neurocysticercosis. Report of the Guideline Development Subcommittee of the American Academy of Neurology.

Bibliographic Source(s)

Baird RA, Wiebe S, Zunt JR, Halperin JJ, Gronseth G, Roos KL. Evidence-based guideline: treatment of parenchymal neurocysticercosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013 Apr 9;80(15):1424-9. [14 references] PubMed External Web Site Policy

Guideline Status

This is the current release of the guideline.

Evidence-based guideline: treatment of parenchymal... [Neurology. 2013] - PubMed - NCBI

2013 Apr 9;80(15):1424-9. doi: 10.1212/WNL.0b013e31828c2f3e.

Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Baird RA, Wiebe S, Zunt JR, Halperin JJ, Gronseth G, Roos KL.

Source

Department of Clinical Neurology, Indiana University School of Medicine, Indianapolis, USA.

Abstract

OBJECTIVE:

To review the evidence base for different treatment strategies in intraparenchymal neurocysticercosis in adults and children.

METHOD:

A literature search of Medline, EMBASE, LILACS, and the Cochrane Database from 1980 to 2008, updated in 2012, resulted in the identification of 10 Class I or Class II trials of cysticidal drugs administered with or without corticosteroids in the treatment of neurocysticercosis.

RESULTS:

The available data demonstrate that albendazole therapy, administered with or without corticosteroids, is probably effective in decreasing both long-term seizure frequency and the number of cysts demonstrable radiologically in adults and children with neurocysticercosis, and is well-tolerated. There is insufficient information to assess the efficacy of praziquantel.

RECOMMENDATIONS:

Albendazole plus either dexamethasone or prednisolone should be considered for adults and children with neurocysticercosis, both to decrease the number of active lesions on brain imaging studies (Level B) and to reduce long-term seizure frequency (Level B). The evidence is insufficient to support or refute the use of steroid treatment alone in patients with intraparenchymal neurocysticercosis (Level U).

PMID:: 23568997; [PubMed - indexed for MEDLINE]
PMCID:: PMC3662271; [Available on 2014/4/9]; Evidence-based guideline: treatment of parenchymal... [Neurology. 2013] - PubMed - NCBI

PubMed is open, however it is being maintained with minimal staffing due to the lapse in government funding. Information will be updated to the extent possible, and the agency will attempt to respond to urgent operational inquiries. For updates regarding government operating status see USA.gov.